Cancer Immunotherapy Developer Armo BioSciences Files for Up-to-$86.25M IPO

Armo BioSciences, a late-stage developer of cancer immunotherapies, will seek to raise up to $86.25 million in gross proceeds through an initial public offering, according to an S-1 registration statement filed with the U.S. Securities and Exchange Commission on the last business day of 2017.Armo has yet to spell out how much it would set aside toward any of several purposes outlined in its S-1 registration statement , filed December 29 and announced by the company that evening after the close o